Investor Day FERMIUM RESEARCH MARKETING TRIP D E C E M B E R 1 6 , 2 0 1 9 FORWARD LOOKING STATEMENTS PolyOne Corporation 2 In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance and/or sales. Loose buffer tube – made of PBT, PTFE, Nylon 12, PP or other polymers.

This is due to the inherent difficulty of forecasting the timing and amount of certain items, such as, but not limited to, restructuring costs, environmental remediation costs, acquisition-related costs, and other non-routine costs. All Rights Reserved 2024 33 Drug delivery devices CATALYZE THE CORE MARKET DRIVERS & NEEDS • Regulatory compliance • Reliable material quality and uninterrupted supply • Supply chain risk mitigation • Global reach $6B ADDRESSABLE MARKET AVIENT END MARKETS, APPLICATIONS AVIENT VALUE PROPOSITION • ISO 13485 accredited sites • Globally approved raw material portfolio • Strict change management • Global supply Auto injectors Syringes Inhalers OTHER APPLICATONS • In-vitro diagnostics • Remote monitoring • Pharma packaging • Catheters • Medical equipment Copyright © . Free cash flow use 2020– 2024 est. 30% 37% 6%27% Debt paydown Dividend payments Share buybacks M&A, other 15% CAGR Copyright © .

Any additional, different or other terms and/or conditions contained in any purchase order, document, website or other communication by or from Buyer are hereby objected to and rejected by Seller. In the event of any claimed conflict between these Terms and any other document not signed by Seller, these Terms shall control. Title and Risk of Loss; Other Risks.

This is due to the inherent difficulty of forecasting the timing and amount of certain items, such as, but not limited to, restructuring costs, environmental remediation costs, acquisition-related costs, and other non- routine costs. Capex / Revenue 2021E (%) Avient is Asset Light Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 1 2 3 3 3 4 3 3 4 5 5 6 7 9 A vi e nt A vi e nt ( E xc l. Avient Specialty Formulators Other Specialty / Chemical Companies A V N T ex .

They use words such as "will," “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning in connection with any discussion of future operating or financial condition, performance and/or sales. This is due to the inherent difficulty of forecasting the timing and amount of certain items, such as, but not limited to, mark-to-market adjustments associated with benefit plans, environmental remediation costs, acquisition-related costs, and other non-routine costs. The presentation of these measures may be different from non-GAAP financial measures used by other companies.

OPS) 21 Sales Adjusted EBITDA $818 $823 2021 2022 + 1% Adjusted EPS + 8% - 3% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 5% excluding FX) Q3 EBITDA BRIDGE (PRO FORMA TOTAL COMPANY) 22 Price increases more than offset raw material and supply chain impacts $ millions CAI: 68Price / Mix (44)Inflation SEM: 41Price / Mix (26)Inflation 39Net Price Benefit (14)Wage and Energy Inflation 6Clariant Color Integration Synergies 14Incentives, Other Employee Costs (11)FX $137 Q3 2022   Adjusted EBITDA $ 142Q3 2021 (39)Demand Q3 2022 SEGMENT PERFORMANCE 23 CAI $587 $566 Sales ($ in millions) $93 $93 EBITDA SEM Pro Forma $326 $319 Sales $70 $62 EBITDA (+ 4% excluding FX) - 4% - 2% (+ 5% excluding FX) Flat (+ 7% excluding FX) - 11% (- 7% excluding FX) $500 $585 Cont. Ops Pro Forma Adjusted EPS (in millions) (in millions) 25 SUMMARY • Executed the plans we laid out earlier this year • Completed the Dyneema acquisition and Distribution divestiture amid challenging market conditions • Paid down debt and expect to finish the year modestly levered at 3.1x net debt to 2022 pro forma adjusted EBITDA • Expect $200 million of free cash flow in 2022 • Entering an economic slowdown with a portfolio that is better positioned than ever before • Updated our EPS guidance to $2.60 from continuing operations APPENDIX Performance Additives 15% Pigments 13% TiO2 11% Dyestuffs 3%Polyethylene 12% Nylon 6% Polypropylene 5% Other Raw Materials 30% Styrenic Block Copolymer 5% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 27 • From Q2 to Q3, we have seen a 7-10% sequential decline in certain hydrocarbon-based raw materials • Other raw materials such as performance additives and pigments have shown moderate inflation sequentially from Q2 to Q3 Annual Purchases RAW MATERIAL AND SUPPLY CHAIN UPDATE Based on 2021 purchases, excludes Avient Protective Materials SEGMENT DATA U.S. & Canada 40% EMEA 35% Asia 20% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 21% Packaging 23% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $585M includes corporate costs.

OPS) 21 Sales Adjusted EBITDA $818 $823 2021 2022 + 1% Adjusted EPS + 8% - 3% (in millions) (in millions) (+ 9% excluding FX) (+ 18% excluding FX) (+ 5% excluding FX) Q3 EBITDA BRIDGE (PRO FORMA TOTAL COMPANY) 22 Price increases more than offset raw material and supply chain impacts $ millions CAI: Price / Mix 68 Inflation (44) SEM: Price / Mix 41 Inflation (26) Net Price Benefit 39 Wage and Energy Inflation (14) Clariant Color Integration Synergies 6 Incentives, Other Employee Costs 14 FX (11) Q3 2022 $137   Adjusted EBITDA Q3 2021 $ 142 Demand (39) Q3 2022 SEGMENT PERFORMANCE 23 CAI $587 $566 Sales ($ in millions) $93 $93 EBITDA SEM Pro Forma $326 $319 Sales $70 $62 EBITDA (+ 4% excluding FX) - 4% - 2% (+ 5% excluding FX) Flat (+ 7% excluding FX) - 11% (- 7% excluding FX) $500 $585 Cont. Ops Pro Forma Adjusted EPS (in millions) (in millions) 25 SUMMARY • Executed the plans we laid out earlier this year • Completed the Dyneema acquisition and Distribution divestiture amid challenging market conditions • Paid down debt and expect to finish the year modestly levered at 3.1x net debt to 2022 pro forma adjusted EBITDA • Expect $200 million of free cash flow in 2022 • Entering an economic slowdown with a portfolio that is better positioned than ever before • Updated our EPS guidance to $2.60 from continuing operations APPENDIX Performance Additives 15% Pigments 13% TiO2 11% Dyestuffs 3%Polyethylene 12% Nylon 6% Polypropylene 5% Other Raw Materials 30% Styrenic Block Copolymer 5% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials 27 • From Q2 to Q3, we have seen a 7-10% sequential decline in certain hydrocarbon-based raw materials • Other raw materials such as performance additives and pigments have shown moderate inflation sequentially from Q2 to Q3 Annual Purchases RAW MATERIAL AND SUPPLY CHAIN UPDATE Based on 2021 purchases, excludes Avient Protective Materials SEGMENT DATA U.S. & Canada 40% EMEA 35% Asia 20% Latin America 5% 2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 21% Packaging 23% Industrial 15% Building and Construction 10% Telecommunications 4% Energy 4% Defense 6% END MARKET REVENUE (1) Total company adjusted EBITDA of $585M includes corporate costs.

For hospitals and other healthcare facilities, infection prevention is critical for improving patient outcomes by reducing the incidence of healthcare- associated infections (HAIs). In some instances, a single exposure to a strong stress cracking agent may cause premature failure, yet in others it may appear to have no effect after numerous applications. In addition to Virex® TB, seven other disinfectants common to the healthcare and consumer industry were tested and the results were recorded in Table 3.

No freedom from any patents or other industrial or intellectual property rights is granted or to be inferred. They also add important characteristics, such as SWELLCOAT® water-blocking, water repellence, adhe- sion, color, and wear and UV-resistance to these and many other applications. We believe that our ongoing commitment to protect the environment, to remain at the forefront of fiber and coating technology, and to ‘treat others as we want to be treated’ will continue to drive the success of our customers, shareholders, and employees.

No freedom from any patents or other industrial or intellectual property rights is granted or to be inferred. They also add important characteristics, such as SWELLCOAT® water-blocking, water repellence, adhe- sion, color, and wear and UV-resistance to these and many other applications. We believe that our ongoing commitment to protect the environment, to remain at the forefront of fiber and coating technology, and to ‘treat others as we want to be treated’ will continue to drive the success of our customers, shareholders, and employees.